STAY CURRENT with FDA-Approved Immunotherapy Treatments from your Office or Home

BOSTON LIVE VIRTUAL ACI PROGRAM INFORMATION
Thursday, Sept. 10, 2020
3–8:30 p.m. EDT

FREE for healthcare professionals, students, patients and patient advocates, the Society for Immunotherapy of Cancer (SITC) Advances in Cancer Immunotherapy™ (ACI) programs are CME-, CNE-, CPE- and MOC-certified and presented by local authorities in tumor immunology and cancer immunotherapy.

ORGANIZERS:
Elizabeth Buchbinder, MD
Dana-Farber Cancer Institute
David F. McDermott, MD
Beth Israel Deaconess Medical Center
Virginia Seery, MSN, RN, ANP-BC
Beth Israel Deaconess Medical Center

ACCREDITATION INFORMATION
AMA Credit Designation
This activity has been approved for AMA PRA Category 1 Credit(s)™.

Pharmacist Credit Designation
This activity is eligible for ACPE credit, see final CPE activity announcement for specific details.

Nursing Credit Designation
This activity is eligible for ANCC contact hours, see final CNE activity announcement for specific details.

BOSTON LIVE VIRTUAL ACI PROGRAM TAKEAWAYS
In addition to networking with fellow colleagues, highlights of the program include:
• Interactive, virtual setting to connect with local faculty and organizers
• Learning how to treat patients with FDA-approved immunotherapies
• A deep dive into identifying and managing irAEs
• COVID-19 considerations from the speakers’ direct experience
• Interpreting new clinical data supporting the use of checkpoint inhibitors, CAR T therapies, cytokines, oncolytic viruses and vaccines

Attendees will able to connect with regional immunotherapy experts during these interactive virtual programs, in subsequent quarterly webinars and through a dedicated SITC CONNECT online community.

For full accreditation information and to register for this event, please visit: sitcancer.org/aci/boston2020

The 2020–2021 ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer in collaboration with the American Academy of Emergency Medicine, the Association of Community Cancer Centers and the Hematology/Oncology Pharmacy Association.

The 2020–2021 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc. and Merck & Co., Inc. (as of Aug. 7, 2020).